Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ:MDGL) granted inducement equity awards on April 1, 2026 to 12 new non-executive employees under its 2025 Inducement Plan.

The company issued a total of 5,758 time-based restricted stock units, vesting in four equal annual installments beginning on the first anniversary, subject to continued employment and approved under Nasdaq Rule 5635(c)(4).

News Market Reaction – MDGL

+0.27%

+0.27% Session close to close

In the Apr 22 session, MDGL gained 0.27%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine equity inducement awards—5,758 time‑based RSUs to 12 new non‑execu...

Analysis

This announcement details routine equity inducement awards—5,758 time‑based RSUs to 12 new non‑executive employees vesting over four years under the 2025 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). Similar grants earlier in 2026 prompted only modest price moves, suggesting the market views them as standard hiring-related dilution. Investors may instead focus on Madrigal’s prior $958.4M in 2025 net sales, conference participation, and ongoing executive equity activity when assessing the broader equity story.

Key Figures

New employees: 12 non-executive employees RSU grants: 5,758 restricted stock units Vesting schedule: 4 equal annual installments +1 more

4 metrics

New employees 12 non-executive employees Recipients of inducement equity awards on April 1, 2026

RSU grants 5,758 restricted stock units Aggregate time-based RSUs granted under 2025 Inducement Plan

Vesting schedule 4 equal annual installments RSUs vest each year on first through fourth anniversaries

Grant date April 1, 2026 Date inducement awards were approved and granted

Historical Context

5 past events · Latest: Apr 07 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 07	Inducement equity grants	Neutral	+1.5%	Inducement RSU grants of 8,079 units to 20 new non-executive hires.
Mar 19	Inducement equity grants	Neutral	-2.9%	Grant of 1,739 time-based RSUs to seven new non-executive employees.
Mar 05	Inducement equity grants	Neutral	-1.5%	Options on 789 shares and 6,882 RSUs granted under inducement plan.
Feb 24	Conference participation	Neutral	+0.5%	Participation in TD Cowen 46th Annual Health Care Conference webcast.
Feb 19	Earnings results	Positive	-11.1%	Strong 2025 net sales and cash balance with multiple strategic milestones.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent Madrigal headlines have often been routine corporate updates (inducement awards, conferences), with only the earnings release showing a clear negative price reaction despite strong reported figures.

Recent Company History

Over the last few months, Madrigal has repeatedly disclosed equity inducement awards under its 2025 Inducement Plan, typically granting time-based RSUs vesting over four years. These announcements on March 1, March 15, and April 1, 2026 resulted in modest price moves of between roughly -3% and +2%. The company also participated in the TD Cowen 46th Annual Health Care Conference on March 3, 2026. In contrast, its Q4 and full-year 2025 results, including net sales of $321.1M for Q4 and $958.4M for 2025, coincided with a sharper -11.11% reaction.

Key Terms

nasdaq listing rule 5635(c)(4), equity inducement awards, restricted stock units

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity inducement awards financial

"it granted equity awards on April 1, 2026 to 12 new non-executive employees as equity inducement awards"

Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.

restricted stock units financial

"The new employees received, in the aggregate, 5,758 time-based restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CONSHOHOCKEN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on April 1, 2026 to 12 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 5,758 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

FAQ

What equity awards did Madrigal (MDGL) grant on April 1, 2026?

Madrigal granted 5,758 time-based restricted stock units in aggregate to 12 new hires. According to the company, the RSUs vest in four equal installments on each of the first through fourth anniversaries of the grant date, subject to continued employment.

How does the vesting schedule for MDGL inducement awards work?

The RSUs vest in four equal annual installments starting one year after grant. According to the company, vesting requires each employee's continued employment on each applicable vesting date.

Why were the MDGL awards approved under Nasdaq Listing Rule 5635(c)(4)?

They were approved because the grants are inducement awards for newly hired employees. According to the company, the independent Compensation Committee approved the awards in accordance with Nasdaq Rule 5635(c)(4).

How many employees received inducement awards from Madrigal (MDGL)?

Twelve new non-executive employees received inducement awards on April 1, 2026. According to the company, the awards were material inducements to accept employment under the 2025 Inducement Plan.

Do Madrigal's inducement RSUs for MDGL create immediate vesting or require service?

The RSUs require continued service; there is no immediate full vesting at grant. According to the company, vesting occurs in four equal installments on each anniversary over four years.

Will the MDGL inducement awards dilute existing shareholders?

The announcement states 5,758 RSUs were issued in aggregate but does not quantify dilution percentage. According to the company, only the aggregate unit count and vesting terms were disclosed, not total share pool impact.